Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer

Authors: Huanzhang Shao, Yinjie Gu, Junli Ding, Peihua Lu, Tingyan Ruan, Wenbin Lu

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Hepatocyte cell adhesion molecule (HEPACAM), a member of immunoglobulin superfamily, is an adhesion molecule. Although dysregulation of several adhesion molecules has been implicated in the progression of non-small cell lung cancer (NSCLC), the expression profile and functions of HEPACAM in NSCLC remains unknown. In this study, it was found that the expression of HEPACAM was downregulated in NSCLC tissues. Forced expression of HEPACAM in NSCLC cells inhibited the growth and migration of the cancer cells, while knocking down the expression of HEPACAM promoted cell growth, migration, and metastasis. In the molecular mechanism study, HEPACAM was found to be a negative regulator of beta-catenin/TCF signaling. Taken together, this study revealed the suppressive roles of HEPACAM in NSCLC and restoring the function of HEPACAM in NSCLC might be a promising strategy for the therapy.
Literature
1.
2.
Lu S, Azada MC, Ou SH. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer. 2015;87:207–9.CrossRefPubMed
3.
Zhong K, Chen W, Xiao N, Zhao J. The clinicopathological significance and potential drug target of E-cadherin in NSCLC. Tumour Biol. 2015;36:6139–48.CrossRefPubMed
4.
Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19:194–204.CrossRefPubMed
5.
Fiori V, Magnani M, Cianfriglia M. The expression and modulation of CEACAM1 and tumor cell transformation. Ann Ist Super Sanita. 2012;48:161–71.CrossRefPubMed
6.
Barrallo-Gimeno A, Estevez R. GlialCAM, a glial cell adhesion molecule implicated in neurological disease. Adv Neurobiol. 2008;8:47–59.CrossRef
7.
Arnedo T, Lopez-Hernandez T, Jeworutzki E, et al. Functional analyses of mutations in HEPACAM causing megalencephalic leukoencephalopathy. Hum Mutat. 2014;35:1175–8.CrossRefPubMed
8.
Tao J, Liu Q, Wu X, et al. Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma. Int J Med Sci. 2013;10:1860–7.CrossRefPubMedPubMedCentral
9.
Moh MC, Zhang T, Lee LH, Shen S. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis. 2008;29:2298–305.CrossRefPubMed
10.
Moh MC, Lee LH, Yang X, Shen S. HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. J Hepatol. 2003;39:580–6.CrossRefPubMed
11.
Tan B, Tan J, Du H, et al. HepaCAM inhibits clear cell renal carcinoma 786–0 cell proliferation via blocking PKCepsilon translocation from cytoplasm to plasma membrane. Mol Cell Biochem. 2014;391:95–102.CrossRefPubMed
12.
Lee LH, Moh MC, Zhang T, Shen S. The immunoglobulin-like cell adhesion molecule hepaCAM induces differentiation of human glioblastoma U373-MG cells. J Cell Biochem. 2009;107:1129–38.CrossRefPubMed
13.
Yang S, Wu X, Luo C, Pan C, Pu J. Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. World J Urol. 2010;28:473–8.CrossRefPubMed
14.
Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhes Migr. 2009;3:334–6.CrossRef
15.
Zhang T, Moh MC, Lee LH, Shen S. The immunoglobulin-like cell adhesion molecule hepaCAM is cleaved in the human breast carcinoma MCF7 cells. Int J Oncol. 2010;37:155–65.CrossRefPubMed
16.
Chung Moh M, Hoon Lee L, Shen S. Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol. 2005;42:833–41.CrossRefPubMed
17.
Song X, Wang Y, Du H, et al. Overexpression of hepacam inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. Prostate. 2014;74:1023–33.CrossRefPubMed
18.
Togashi Y, Hayashi H, Terashima M, et al. Inhibition of beta-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. J Thorac Oncol. 2015;10:93–101.CrossRefPubMed
19.
Fan C, Jiang G, Zhang X, et al. Zbed3 contributes to malignant phenotype of lung cancer via regulating beta-catenin and P120-catenin 1. Mol Carcinog. 2015;54 Suppl 1:E138–47.CrossRefPubMed
20.
21.
Yan HB, Wang XF, Zhang Q, et al. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis. 2014;35:867–76.CrossRefPubMed
22.
Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004;64:1987–96.CrossRefPubMed
Metadata
Title
HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer
Authors
Huanzhang Shao
Yinjie Gu
Junli Ding
Peihua Lu
Tingyan Ruan
Wenbin Lu
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4084-9

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation

Original Article

Apoptotic effect of tannic acid on fatty acid synthase over-expressed human breast cancer cells

Original Article

RETRACTED ARTICLE: The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer

Original Article

Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells

Original Article

Lipase member H frequently overexpressed in human esophageal adenocarcinomas

Original Article

Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits